key: cord-0947133-q6lbwglz
authors: Martínez-Iglesias, Olaia; Naidoo, Vinogran; Carrera, Iván; Cacabelos, Ramón
title: Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer’s Disease
date: 2022-02-23
journal: Int J Mol Sci
DOI: 10.3390/ijms23052446
sha: 39817e75e4600d696c19d6c48e8078c6082454e1
doc_id: 947133
cord_uid: q6lbwglz

Alzheimer’s Disease (AD) is a major health problem worldwide. The lack of efficacy of existing therapies for AD is because of diagnosis at late stages of the disease, limited knowledge of biomarkers, and molecular mechanisms of AD pathology, as well as conventional drugs that are focused on symptomatic rather than mechanistic features of the disease. The connection between epigenetics and AD, however, may be useful for the development of novel therapeutics or diagnostic biomarkers for AD. The aim of this study was to investigate a pathogenic role for epigenetics and other biomarkers in the male APP/BIN1/COPS5 triple-transgenic (3xTg) mouse model of AD. In the APP/BIN1/COPS5 3xTg-AD mouse hippocampus, sirtuin expression and activity decreased, HDAC3 expression and activity increased, PSEN1 mRNA levels were unchanged, PSEN2 and APOE expression was reduced, and levels of the pro-inflammatory marker IL-6 increased; levels of pro-inflammatory COX-2 and TNFα and apoptotic (NOS3) markers increased slightly, but these were non-significant. In fixed mouse-brain slices, immunoreactivity for CD11b and β-amyloid immunostaining increased. APP/BIN1/COPS5 3xTg-AD mice are a suitable model for evaluating epigenetic changes in AD, the discovery of new epigenetic-related biomarkers for AD diagnosis, and new epidrugs for the treatment of this neurodegenerative disease.

Neurodegenerative disorders (NDDs) are major public health problems and are usually linked to ageing. Alzheimer's disease (AD) is the leading cause of dementia (>50%), affecting 45-50 million individuals worldwide [1] ; over 58% of these patients live in lowand middle-income countries [2] . The prevalence of all-cause dementia is estimated to rise from 50 million in 2010 to 113 million by 2050 [3, 4] . AD affects an estimated 6.2 million Americans aged 65 years and older. Unless medical breakthroughs are made to prevent, halt, or cure AD, this figure could rise to 13.8 million people by 2060. According to official death records, AD was the sixth-leading cause of death in the United States in 2019, and the fifth-leading cause of death among Americans 65 years and older. Fatalities from stroke, heart disease, and HIV declined between 2000 and 2019; however, recorded deaths from AD increased by more than 145% during this same period [5] . This increased trajectory in the number of AD-related fatalities was likely exacerbated in 2020 by the COVID-19 pandemic [5] . Despite significant effort over the past 50 years, no successful therapeutic outcomes have been achieved, and anti-AD drugs are not cost-effective [6] . New biomarkers that allow the early diagnosis and treatment of AD are, therefore, required.

AD is progressive and causes an irreversible loss of memory and cognitive function [1] . The main pathological hallmarks of AD are neuritic plaques and intracellular neurofibrillary tangles, which are related to the accumulation of the amyloid-beta peptide (Aβ) and hyperphosphorylated microtubule-associated tau protein, respectively [7, 8] . AD is a complex

The primary degenerative effect in AD is irreversible neuronal deterioration, caused in part by the activation of inflammatory processes that induce apoptotic pathways and subsequent necrosis, resulting in massive neuronal death. Figure 1A -D' highlights the neurodegenerative process observed in the APP/BIN1/COPS5 3xTg-AD mouse brain, with CD11b as a marker of inflammation ( Figure 1A ',D'), GFAP as an astroglial marker ( Figure 1B') , and β-amyloid as a marker of extracellular plaque deposits ( Figure 1C' ). Compared to the wild-type mouse brain ( Figure 1A -D), these markers showed strong immunoreactivity in the neocortex (Ctx) and hippocampus ( Figure 1A -C). The mean distribution areas of these markers were quantified in each section from both experimental groups with Pixcavator 4.0 software ( Figure 1D ). Compared to control mice, CD11b immunoreactivity in APP/BIN1/COPS5 3xTg-AD mice increased approximately three-fold in the cortex, thalamus, and hypothalamus ( Figure 1A ,A',D,D'), GFAP-immunoreactivity increased two-fold in the hippocampus ( Figure 1B,B') , and many β-amyloid plaques were observed only in the APP/BIN1/COPS5 3xTg-AD mouse brain ( Figure 1C ,C'). Astroglial (GFAP-positive, +) and microglial immune responses (CD11b+) are strong in areas of the brain vulnerable to neurodegeneration; the correlation between these markers indicates the reliability of this model. Taken together, these data revealed that APP/BIN1/COPS5 3xTg-AD mice exhibit an extensive pattern of neuroinflammation that correlated with acute neurodegenerative pathologies, highlighted by increased Aβ deposition, substantial neuroinflammation, and cell death in the neocortex and hippocampus.

Is Regulated in APP/BIN1/COPS5 3xTg-AD Mice PSEN1 and PSEN2 are genes that encode the major component of γ-secretase, which is responsible for the sequential proteolytic cleavage of amyloid precursor proteins and the production of β-amyloid peptides. Since alterations in PSEN2 expression may be a risk factor for AD, we examined PSEN1 and PSEN2 expression in hippocampal samples from wildtype and APP/BIN1/COPS5 3xTg-AD mice. PSEN1 mRNA levels were not significantly different between wild-type and APP/BIN1/COPS5 3xTg-AD mice ( Figure 2 ); PSEN2 mRNA levels, however, decreased by approximately 70% in these mice ( Figure 2 ). The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for late-onset AD [36] . We therefore analyzed APOE mRNA levels in the hippocampus of wild-type and APP/BIN1/COPS5 3xTg-AD mice; APOE expression in APP/BIN1/COPS5 3xTg-AD mice decreased significantly by about 65% (p < 0.05) ( Figure 2 ). These findings suggest that APP/BIN1/COPS5 3xTg-AD mice accurately reproduce changes in gene expression associated with AD [37] , and are a good preclinical model for studying this neurodegenerative disorder.

As inflammation is a key mechanism in AD, we examined the expression of tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) in the hippocampus of wild-type and APP/BIN1/COPS5 3xTg-AD mice. In transgenic mice, TNFα expression increased modestly, but this was not significant ( Figure 3A ). IL-6 expression, however, was nearly twenty times higher in APP/BIN1/COPS5 3xTg-AD mice than in wild-type animals (p < 0.05) ( Figure 3A ). These data suggest that the APP/BIN1/COPS5 3xTg-AD mouse model replicates the influence of IL-6 on the inflammatory cascade in patients with AD.

Increased nitric oxide synthase 3 (NOS3) expression is associated with cortical neuronal death in AD [38, 39] . NOS3 expression slightly increased in APP/BIN1/COPS5 3xTg-AD mice ( Figure 3B ). Cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes and neuronal activity, is upregulated in the AD brain [40, 41] . In the current study, we detected a slight increase in COX-2 expression in the APP/BIN1/COPS5 3xTg-AD mouse hippocampus ( Figure 3B ), confirming that APP/BIN1/COPS5 3xTg-AD mice are an accurate model for studying AD-like pathology. APP/BIN1/COPS5 3xTg-AD mouse brain than in controls (D'). (E) Quantification of data ind the average percentage of immunoreactive markers in the experimental groups. * p < 0.05. Sca 100 μm. Amyg, amygdala; βA, β-amyloid; CA1, hippocampal formation; CD11b, inflam marker; Ctx, cortex; DAPI, nuclear marker; DG, dentate gyrus; GFAP, glial fibrillary acidic p Th, thalamus; Ent Ctx, entorhinal cortex; Hypoth, hypothalamus; SN, substantia nigra; VTA, tegmental area.

PSEN1 and PSEN2 are genes that encode the major component of γ-secretase, is responsible for the sequential proteolytic cleavage of amyloid precursor protei the production of β-amyloid peptides. Since alterations in PSEN2 expression may b factor for AD, we examined PSEN1 and PSEN2 expression in hippocampal sample wild-type and APP/BIN1/COPS5 3xTg-AD mice. PSEN1 mRNA levels we significantly different between wild-type and APP/BIN1/COPS5 3xTg-AD mice ( 2); PSEN2 mRNA levels, however, decreased by approximately 70% in these mice ( 2) . The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor fo onset AD [36] . We therefore analyzed APOE mRNA levels in the hippocampus o type and APP/BIN1/COPS5 3xTg-AD mice; APOE expression in APP/BIN1/COPS5 AD mice decreased significantly by about 65% (p < 0.05) ( Figure 2 ). These findings s that APP/BIN1/COPS5 3xTg-AD mice accurately reproduce changes in gene expr associated with AD [37] , and are a good preclinical model for studyin neurodegenerative disorder. As inflammation is a key mechanism in AD, we examined the expression of necrosis factor alpha (TNFα) and interleukin-6 (IL-6) in the hippocampus of wil and APP/BIN1/COPS5 3xTg-AD mice. In transgenic mice, TNFα expression inc modestly, but this was not significant ( Figure 3A ). IL-6 expression, however, was twenty times higher in APP/BIN1/COPS5 3xTg-AD mice than in wild-type anima 0.05) ( Figure 3A ). These data suggest that the APP/BIN1/COPS5 3xTg-AD mouse replicates the influence of IL-6 on the inflammatory cascade in patients with AD. 

In recent years, there has been increasing evidence demonstrating the involvement of several epigenetic mechanisms in AD. Sirtuin proteins, together with deacetylase and ADPribosyltransferase activity, may provide beneficial effects against age-related disorders [42] . SIRT activity decreased significantly by 15% in the APP/BIN1/COPS5 3xTg-AD mouse hippocampus compared to wild-type controls (p < 0.05) ( Figure 4A ). Moreover, SIRT1 mRNA levels decreased by approximately 50% in AD transgenic mice ( Figure 4B ); there were no differences in SIRT2 mRNA expression between both experimental groups (data not shown). 

HDAC inhibitors have the potential to treat neurological disorders, such as AD [43, 44] . We therefore analyzed HDAC activity and HDAC3 mRNA levels in wild-type and APP/BIN1/ COPS5 3xTg-AD mice; HDAC activity and HDAC3 mRNA expression increased by approximately 40% in the hippocampus from APP/BIN1/COPS5 3xTg-AD mice ( Figure 5A ,B). These findings indicate that APP/BIN1/COPS5 3xTg-AD mice are a useful animal model for studying the contribution of epigenetics to AD. 

The difficulty of obtaining AD brain tissues presents a major obstacle in AD research. Therefore, mouse models that better mimic human AD-related pathology are critical for the evaluation of therapeutic strategies against this neurodegenerative disorder. In the current study, APP/BIN1/COPS5 3xTg-AD mice showed important brain degenerative hallmarks, such as neuroinflammation, Aβ deposition, and cell death. With respect to the genes that form the basis for the generation of APP/BIN1/COPS5 transgenic mice, mice overexpressing human APP, COPS5, and BIN1 [15] show severe deficits in learning and memory [13, 45, 46] .

Brain-derived neurotrophic factor (BDNF) regulates neuronal development, differentiation, and survival by protecting against tau-related neurodegeneration [47] and is critical to brain health [48, 49] . However, deficient BDNF activity underlies neurodegeneration in AD, although exactly how BDNF participates in AD pathology remains unclear. BDNF expression is decreased in hippocampal and cortical neurons from 21-month APP/BIN1/COPS5 3xTg-AD mice [50] , and is strongly reduced in buffy coat samples from patients with dementia or PD than in healthy control subjects [51] . In the current study, our findings revealed that the expression levels of two important genes in AD-like disease, PSEN2 and APOE, are altered in the APP/BIN1/COPS5 3xTg-AD mouse brain. Alterations in PSEN2 expression may be a risk factor for AD [52] . Natural compounds that enhance brain apoE levels are potentially therapeutic, given that APOE mRNA levels are regulated by nuclear receptors, retinoid X receptors (RXRs), and hepatic X receptors (LXRs) [53] . Oral administration of the RXR agonist bexarotene, for example, increases apoE levels, reduces Aβ deposition, and improves cognitive functions in APP/PS1 mice [54] . Clinically, four weeks of bexarotene treatment does not reduce brain amyloid burden; the AD patient sample size (n = 20, randomized to receive treatment or placebo), however, was small (ClinicalTrials.gov identifier NCT01782742) [55] . RXR heterodimers, including thyroid hormone receptor (TR)/RXR, retinoid acid receptor (RAR)/RXR or peroxisome proliferator-activated receptor γ (PPARγ)/RXR, regulate apoE brain levels, which may serve as targets for the development of anti-AD therapeutics [2, 23, 56, 57] . Our data show that APOE is downregulated in APP/BIN1/COPS5 3xTg-AD mice, suggesting that these mice are suitable for studying the effect of drugs that regulate APOE function.

Neuroinflammation is critical to the progression of AD pathogenesis. IL-6 levels are increased in AD patients [58, 59] and are linked to diffuse plaques, representing the early stage of plaque formation [59] . Aβ induces IL-6 expression in microglia and astrocyte cell cultures [59] ; IL-6 also induces AD-type tau phosphorylation [60] . TNFα, a critical mediator of the inflammatory response, is secreted by astrocytes and microglia in the brain [59] . TNFα is one of the most well-defined cytokines during AD pathogenesis and is correlated with cognitive decline, neuronal toxicity, and cerebral apoptosis [59] . Increased TNFα expression is found in several regions in the brains of patients with AD [61] . Aβ induces microglial activation and TNFα release, and plays a deleterious role in inducing neuronal death in 3xTg-AD mice [59, 62] . In this study, we found a slight increase in TNFα expression and a strong increase in IL-6 levels in the hippocampus of APP/BIN1/COPS5 3xTg-AD mice compared to wild-type controls. As mentioned earlier, NOS3 is related to apoptosis and COX-2 is associated with inflammation [38] [39] [40] [41] . In the present study, transgenic mice showed altered NOS3 and COX-2 expression. However, differences in NOS3, COX-2, and TNFα expression between wild-type and APP/BIN1/COPS5 3xTg-AD mice were not statistically significant. This may be because of the number of mice (n = 4 per group) used in the study. Our findings suggest that this model is useful for studying apoptosis and inflammation-related gene expression that influence AD pathology; however, further studies using a higher number of animals are needed. COX-2 inhibition is a proposed strategy for treating patients with AD [63] ; non-steroidal anti-inflammatory drugs that selectively inhibit COX-2 reduce the risk of developing AD in a normal-ageing population [64] . Triple-transgenic AD mice may therefore be a valuable preclinical model for testing the effect of drugs that target COX-2 production.

DNA methylation and chromatin remodeling/histone modifications are important epigenetic mechanisms and are promising approaches for the management of AD [65, 66] . Global DNA methylation is downregulated in the hippocampus [27] and peripheral blood mononuclear cells in patients with AD [67] . Global DNA methylation is also reduced in the brain, liver, and serum of APP/BIN1/COPS5 3xTg-AD mice; moreover, DNMT3a expression is lower in the APP/BIN1/COPS5 3xTg-AD brain than in wild-type mice [21] . Previously, our group showed that global DNA methylation is decreased in buffy coat samples from patients with AD and other types of dementia, such as vascular or mixed dementia [21, 51] . DNMT3a expression was also reduced in buffy coat samples from patients with different neurodegenerative disorders, including AD [51] . These date indicate that DNA methylation is an important biomarker for the diagnosis of neurodegenerative disorders, including AD. There is, furthermore, an age-related increase in DNA hydroxymethylation in the brains of patients with AD [26, 56] . In an earlier study, we found that DNA methylation levels improve after treatment with AtreMorine, a bioproduct with potent neuroprotective and dopamine-enhancing capabilities [68] . In APP/BIN1/COPS5 3xTg-AD mice, AtreMorine increases global DNA methylation in brain, liver, and serum samples, with a concomitant increase in DNMT3a expression in the central nervous system [68] .

Acetylation is dysregulated in AD and negatively impacts memory and cognition [69, 70] . Histone H4 acetylation decreases with age in wild-type mice but increases with age in 3xTg-AD mice [50] . Hippocampal/cortical neurons from young (2-11 month) 3xTg-AD mice respond differently to HDAC inhibition compared to wild-type animals; these transgenic mice are sensitive to the HDAC inhibitor trichostatin A (TSA) early in life (2-11 months) but become insensitive in old age (21 months) [50] . Neurons from non-transgenic mice are TSA-insensitive at young ages but become sensitive at middle-age (8 months) [50] . The contribution of sirtuins in AD has become increasingly clear; SIRT1, for example, regulates APP processing, neuroinflammation, neurodegeneration, and mitochondrial dysfunction in AD [71] . The injection of SIRT1 into the hippocampus of p25 transgenic mice protects against neurodegeneration [72] . Moreover, SIRT1 overexpression reduces tau acetylation and attenuates tau pathology in tau P301S transgenic mice [73] . SIRT1 overexpression, furthermore, reduces AD pathology and decreases the formation of β-amyloid protein and senile plaques in APPSWE/ind (J20) and APPswe/PS1M146L (APP/PS1) mice [71] . Therefore, since SIRT1 overexpression is protective against AD [72] , enhancing SIRT1 enzyme activity is an attractive target for investigating novel treatment options in AD [74] . One of the most potent activators of SIRT is resveratrol, a natural chemical found in grapes and red wine that increases SIRT1 activation over ten-fold [74, 75] . A variety of synthetic resveratrol derivatives produce lower toxicity and higher potency in the HEK293 cell line and Saccharomyces cerevisiae [75] . Several synthetic SIRT activators (e.g., SRT1720, SRT2104, 1,4-dihydropyridine, or UBCS039) activate different SIRTs [57] . SRT1720 and SRT2104 activate SIRT1, 1,4-dihydropyridine activates SIRTs 1-3, and UBCS039 activates SIRT 5 and SIRT6 [57] . In the present study, SIRT activity and SIRT mRNA levels were lower in APP/BIN1/COPS5 3xTg-AD than in wild-type mice; the transgenic AD mouse model used in this study is appropriate for exploring SIRT regulatory mechanisms and SIRT-based therapies for AD. Sirtuin concentrations in saliva can be used for the non-invasive diagnosis of AD in patients of advanced age [76] . SIRT1 concentrations, measured by surface plasmon resonance, western blot, and enzyme-linked immunosorbent assays are substantially lower in AD patients than in non-AD patients; this suggests that SIRT1 is a predictive marker during the early stages of AD [77] . SIRT1, SIRT3, and SIRT6 blood circulatory levels are significantly decreased in AD [78] . Our research group previously showed the importance of SIRT2-related genophenotypes and their implications for AD susceptibility and clinical treatment response [79] .

HDAC3 overexpression in the hippocampus of 6-month-old APP/PS1 mice increases Aβ levels, activates microglia, and decreases dendritic spine density [3] . HDAC3 inhibition, however, reverses AD-related pathologies in APP (hAPP695, Swedish mutation), PS1 (PSEN1, M146V), and tau (hTau-4R0N-P301L) mutant mice [31] . HDAC inhibitors, initially used as anti-cancer drugs, may be neuroprotective as they enhance synaptic plasticity and learning and memory in patients with AD [80] . In clinical trials with patients with AD, HDAC inhibitors such as valproate (VPA), suberoylanilide hydroxamic acid (SAHA; Vorinostat), TSA, and sodium butyrate improve memory and reduce cognitive deficits and endogenous Aβ production [44] . The data in the present study support published evidence that HDAC3 inhibition reverses AD-related pathologies in vitro and in vivo, including the 3xTg-AD mice model [31] .

There have been promising findings related to blood-based epigenetic biomarkers in AD-based research. However, inconsistencies in research design, technology, the platforms used for biomarker testing, and statistical analysis methodologies have impeded further progress. In fact, relatively few findings have been independently replicated across different research groups [81] . This study, therefore, demonstrates that the APP/BIN1/COPS5 3xTg-AD mouse model is a useful tool for studying novel epigenetic biomarkers for the diagnosis and treatment of AD, with the potential for enhancing translatability.

All experimental procedures were performed in accordance with the European Community Law (86/609/EEC), European Union Directive 2016/63/EU, and the Spanish Royal Decree (R.D. 1201/2005). Study procedures were reviewed and approved by the Ethics Committee of the International Center of Neuroscience and Genomic Medicine.

Wild-type C57BL/6 (n = 4) and APP/BIN1/COPS5 3xTg-AD (n = 4) male mice were bred from colonies originally donated by Dr. Madepalli Lakshmana (Departments of Immunology and Nano-Medicine, Florida International University, Miami, FL, USA). These mice overexpress the Swedish mutation of human APP, bridging integrator 1 (BIN1), and COP9 constitutive photomorphogenic homolog subunit 5 (COPS5). To distinguish the APP/BIN1/COPS5 model from the well-known 3xTg-AD mouse model (B6;129-Tg(APPSwe,tauP301L)1Lfa-Psen1TM1Mpm/Mmjax), APP/BIN1/COPS5 3xTg-AD refers to the transgenic mice used in the current study. The APP/BIN1/COPS5 3xTg-AD mice were generated at the Sylvester Comprehensive Cancer Center Transgenic Core Facility (University of Miami), using C57BL/6 mice as the background strain. DNA constructs and procedures for the generation of transgenic mice have been previously described [12, 45, 82] . Nine-month-old mice were housed in an air-conditioned room (22 ± 0.5 • C and 50-60% humidity) under a 12-h light/12-h dark cycle with access to standard laboratory food and water ad libitum. Four animals per experimental group were used.

Mice were genotyped by the polymerase chain reaction (PCR) using genomic DNA from tail samples as templates. Genomic DNA was extracted using a High Pure PCR Template Preparation Kit (Roche, Basel, Switzerland), according to the manufacturer's specifications. An UltraRun Long Range PCR Kit (Qiagen, Venlo, The Netherlands) and Phire Hot Start II DNA Polymerase (ThermoFisher) were used for APP and BIN/COPS5 amplification, respectively. The primers used are shown in Table 1 and PCR conditions in Table 2 . IL-2 primers were used as controls for DNA extraction and amplification. 

Wild-type C57BL/6J or APP/BIN1/COPS5 3xTg-AD male mice (n = 4 per group; 8-11 weeks-old) were anesthetized with diethyl ether (Panreac, Darmstadt, Germany), and transcardially perfused with phosphate-buffered saline (PBS, pH 7.4). Brains were collected, washed briefly in PBS, and the hemispheres separated. The left hemispheres were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and stored at 4 • C for 48 h.

Hippocampi were isolated from the right hemispheres and placed into RNA later solution (Qiagen) for RNA extraction or stored at −80 • C for nuclear extraction. For immunohistochemistry, the left hemispheres were cryoprotected in 30% sucrose solution in 0.1 M phosphate buffer, and cryosectioned. Parallel series of transverse sections (40-50 µm) were obtained with a cryostat (Starlet 2212, Bright; Luton, UK) and mounted on Superfrost Plus (Menzel-Gläser, Braunschweig, Germany) slides.

Brain sections were rinsed twice for 10 min each in PBS at pH 7.4, and then incubated in nonspecific binding blocking solution (0.1 M PBS containing 0.2% Tween-20 and 15% normal goat serum; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) for 1 h at room temperature (RT). The sections were then incubated overnight at 4 • C with primary antibodies (see Table 3 ), diluted in blocking buffer. Negative primary controls included tissues treated with blocking solution but without the addition of primary antibodies. The sections were then washed in PBS and incubated with Alexa-488-or Alexa-594-conjugated secondary antibodies (ThermoFisher Scientific, Waltham, MA, USA), diluted 1:500 in blocking buffer, for 2 h, at RT. The tissues were then washed three times with PBS, counterstained with 4 ,6-diamidino-2-phenylindole (DAPI) for 15 min, and coverslipped with Vectashield antifade mounting medium (Vector Labs, Burlingame, CA, USA). Immunostained images were captured with a Leica DM6 B upright microscope (Leica Microsystems, Northbrook, IL, USA) and Leica Application Suite X (LAS X) software version 3.5.5. For each tissue section, area/pixel analysis software (Pixcavator 4) was used to quantify the number of pixels inside the outer boundary of each cell body; this aided quantification of the density of immunofluorescence cell markers relative to background. Purified RNAs (400 ng) were retrotranscribed into DNA according to the specifications of the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA), under the following thermocycling conditions: 25 • C (10 min), 37 • C (120 min), and 85 • C (5 min).

Gene expression was quantified by qPCR using the StepOne Plus Real Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA), following manufacturer's instructions. Each PCR reaction was performed in duplicate with the TaqMan Gene Expression Master Mix (Thermo Fisher) and specific TaqMan probes (Thermo Fisher) ( Table 4 ). Relative quantification was performed using the comparative CT method [27] with StepOne Plus Real Time PCR software and are expressed as fold induction with respect to healthy samples. Data were normalized to mouse S18 ( Table 2 ) mRNA levels. Data are shown as mean ± S.E.M. 

Sirtuin and HDAC activities were measured by a colorimetric Sirtuin Activity/Inhibition kit (EpiGentek, New York, NY, USA) or HDAC Activity/Inhibition kit (EpiGentek, New York, NY, USA), respectively, following the manufacturer's instructions. Briefly, nuclear protein extract (50 ng) was transferred to wells that contained an acetylated histonederived substrate. The plate was then incubated at 37 • C for 90 min, after which the wells were rinsed with 1× wash buffer, and capture and detection antibodies added. The amount of deacetylated product, proportional to SIRT and HDAC enzyme activities, was measured at 450 nm in an Epoch Microplate Reader. Absorbance at 655 nm was used as the reference.

Levene's test and the Shapiro-Wilk test were used to test for the equality of variances and normality, respectively. Statistical significance was determined with unpaired t tests (SPSS software Version 22.0, IBM, Armonk, NY, USA). Data are expressed as mean ± S.E.M, and p < 0.05 was considered statistically significant.

In this study, we evaluated the potential of the APP/BIN1/COPS5 triple-transgenic mouse model for epigenetics-related AD research. It is important to note, however, that our findings are specific to male APP/BIN1/COPS5 3xTg-AD mice. These mice exhibited neuroinflammation and Aβ deposition, which are hallmarks of AD. Furthermore, the expression of three AD-related genes (PSEN1, PSEN2 and APOE) was altered. SIRT and HDAC activity and expression were also altered. These data suggest that the APP/BIN1/COPS5 3xTg-AD mouse model is reliable for developing and testing novel epigenetic biomarkers or epidrugs against AD pathology.

The APP/BIN1/COPS5 mouse model of AD used in this study addresses the earlyonset neurodegenerative consequences of Aβ deposition. We did not conduct behavioral tests with this model because the main aim of our study was to investigate a pathogenic role for epigenetics and other biomarkers in the male APP/BIN1/COPS5-3xTg mouse model of AD. Since over 65% of AD cases occur in females, it is important to study AD pathogenesis in female mice. However, female APP/BIN1/COPS5 mice were not used in the current study because we detected a dopaminergic component, exclusively, in the brains of these mice (unpublished data). Our future goal is to investigate the contribution of the dopaminergic system in female APP/BIN1/COPS5 3xTg-AD mice, incorporating molecular and behavioral data; this will have important implications for future drug discovery and clinical trials for AD in terms of targeted sex-specific responses to AD therapeutics. A further limitation of this study is that we did not include a comparison between APP/BIN1/COPS5 mice and the well-known 3xTg-AD and/or 5xFAD transgenic mouse models of AD. However, our future work will address this limitation through behavioral testing, the assessment of cognitive function, and molecular analyses in male and female APP/BIN1/COPS5-and 5xFAD mice. 

The authors declare no conflict of interest.

Can cloud-based tools accelerate Alzheimer's drug discovery?

Alzheimer's disease facts and figures

Dementia time to death: A systematic literature review on survival time and years of life lost in people with dementia

Alzheimer's Diseases Facts and Figures

Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?

Molecular genetics of Alzheimer's disease and aging

Pharmacogenetic considerations in the treatment of Alzheimer's disease

Pharmacogenetics of vascular risk factors in Alzheimer's disease

Cerebral perfusion enhancing intervention: A new strategy for the prevention of Alzheimer's disease

Characterization of the 3xTg-AD mouse model of Alzheimer's Disease: Part Behavioral and cognitive changes

Pivotal role of the RanBP9-cofilin pathway in Ab-induced apoptosis and neurodegeneratiom

RanBP9 overexpression down-regulates phosphocofilin, causes early synaptic deficits and impaired learning, and accelerates accumulation of amyloid plaques in the mouse brain

Planel, E. Cognitive and non-cognitive behaviours in the triple transgeinic mouse model of Alzheimer's Disease expressing mutated APP, PS1 and MAPT (3xTg-AD)

Comparative characterization of transgenic mouse models of Alzheimer's disease

Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies

The emerging field of neuroepigenetics

The epigenetic machinery in the lyfe cycle and pharmacoepigenetics

Opening up the DNA methylome of dementia

Epigenetics of dementia: Understanding the disease as a transformation rather than a state

DNA methylation in Neurodegenerative and Cerebrovascular Disorders

Epigenetics and gene expression

Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease

Pharmacoepigenomic interventions as novel potential treatment for Alzheimer's Disease and Parkinson's Disease

Epigenetic basis of Alzheimer disease

Agedependent increment of hydroxymethylation in the brain cortex in the triple-trangenic mouse model of Alzheimer's disease. J. Alzheimer's Dis

van den hove, D. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients

Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain

Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation

Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease

Inhibition of HDAC3 reverses Alzheimer's disease-realted pathologies in vitro and in the 3xTg-AD mouse model

HDAC3 is a critical negative regulator of long-term memory formation

HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease

The acetylation of tau inhibits its function and promotes pathological tau aggregation

Sirtuin 1 reduction parallels the accumulation of tau in Alzheimerñs disease

Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function

Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery

Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: Relevance to alxheimer's type degeneration

COX-2 expression in brains of patients with familiar Alzheimer's disease

The role of COX-1 and COX-2 in Alzheimer's Disease Patholgy and the therapeutic potentials of non-steroidal anti-inflammatory drugs

Sirtuins and their biological relevance in aging and age-related disorders

Histone deacetylases inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronals Differentiation

Epigenetic treatment of neurodegenerative disorders

Aberrant accrual of BIN1 near Alzheimer's disease amyloid deposits in transgenic models

COPS5 protein overexpression increases amyloid plaque burden, decreases spinophilin-immuroreactive puncta, and exarcebates learning and memory deficits in the mouse brain

Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease

Brain-Derived neurotrophic factor: A key molecule for memory in the healthy and pathological brain

Serum BDNF as a potential biomarker of Alzheimer's Disease: Verification through assessment of serum, cerebrospinal fluid, and medial temporal lobe atrophy

Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease

Epigenetic Biomarkers as diagnostic tools for Neurodegenerative Disorders

PSEN1 and PSEN2 gene expression in Alzheimer's disease brain a new approach

Apoliporotein E as a therapeutic target in Alzheimer's disease: A review of basic research and clinical evicende

ApoE-directed therapeutics rapidly clear betaámyloid and reverse deficits in AD mouse models

Double-blind, placebo-cpmtrolled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimer's Res

What is the gold standard model for Alzheimer's disease drug discovery and development?

Sirtuin activators and inhibitors:promises, achievements and challenges

Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer's Disease

Peripheral inflammatory biomarkers in Alzheimer's disease: A brief review

Interleukin-6 induces Alzheimer-type phosporylation of tau protein by deregulating the cdk5/p35 pathway

The induction of the TNFalpha death domain signaling patwhway in Alzheimer's disease brain

Chronic neuron-specific tumor necrosis factor alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice

Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease

Zagol-Ikapitte, I.; et al. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice

DNA methylation: A promising approach in manegement of Alzheimer's Disease and other Neurodegenerative Disorder

Epigenetic modifications in Alzheimer's neuropathology and therapeutics. Front. Neurosc

Global changes in DNA methylation in Alzheimer's disease peripheral blood mononuclear cells

AtreMorine treatment regulates DNA methylation in Neurodegenerative Disorders: Epigenetic and pharmacogenetic studies

Histone acetylation modifiers in the pathogenesis of Alzheimer's Disease. Front Cell Neurosci

The contribution and therapeutic potential of epigenetic modifications in Alzheimer's Disease

Sirtuin 1 and Alzheimer's disease: An up-to-date review

The effects of SIRT1 on Alzheimer's Disease models

Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy

Cacabelos Neuroprotection with natural antioxidants and nutraceuticals in the context of brain cell degeneration: The epigenetic connection

Design and synthesis of compounds that extend yeast replicative lifespan

Sirtuins as possible predictors of aging and Alzheimer's Disease development: Verification in the hippocampus and saliva

Sirtuin1: A primising serum protein marker for early detection of Alzheimers disease

Blood circulatory level of seven sirtuins in Alzheimer's Disease: Potent biomarker based on translational reseach

Sirtuins in Alzheimer's Disease-SIRT2-related GenoPhenotypes and implication in Pharmacoepigenetics

Targeting HDACs: A promising therapy for Alzheimer's Disease

The current status of blood epigenetic biomarkers for dementia

Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4-10 Prevents Spatial Learning Decline

Tristetraprolin Limits Inflammatory Cytokine Production in Tumor-Associated Macrophages in an mRNA Decay-Independent Manner

Age-dependent behavioral and biochemical characterization of single APP knock-in mouse (APPNL-G-F/NL-G-F) model of Alzheimer's disease